CH620927A5 - Process for the preparation of 3-alkyl-7-oxoalkylxanthines - Google Patents
Process for the preparation of 3-alkyl-7-oxoalkylxanthines Download PDFInfo
- Publication number
- CH620927A5 CH620927A5 CH1561475A CH1561475A CH620927A5 CH 620927 A5 CH620927 A5 CH 620927A5 CH 1561475 A CH1561475 A CH 1561475A CH 1561475 A CH1561475 A CH 1561475A CH 620927 A5 CH620927 A5 CH 620927A5
- Authority
- CH
- Switzerland
- Prior art keywords
- carbon atoms
- alkyl
- water
- shark
- oxoalkylxanthines
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 11
- 238000002360 preparation method Methods 0.000 title claims description 5
- 125000004432 carbon atom Chemical group C* 0.000 claims description 20
- 125000000217 alkyl group Chemical group 0.000 claims description 11
- 150000001875 compounds Chemical class 0.000 claims description 11
- -1 alkali metal salt Chemical class 0.000 claims description 7
- 229910052736 halogen Inorganic materials 0.000 claims description 4
- 241000251730 Chondrichthyes Species 0.000 claims description 3
- 229910052783 alkali metal Inorganic materials 0.000 claims description 3
- 125000001424 substituent group Chemical group 0.000 claims description 3
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 2
- 239000002152 aqueous-organic solution Substances 0.000 claims description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 2
- 229910052794 bromium Inorganic materials 0.000 claims description 2
- 229910052801 chlorine Inorganic materials 0.000 claims description 2
- 239000000460 chlorine Substances 0.000 claims description 2
- 150000002367 halogens Chemical class 0.000 claims description 2
- 125000002947 alkylene group Chemical group 0.000 claims 2
- 125000001246 bromo group Chemical group Br* 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 16
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 15
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 15
- 239000000203 mixture Substances 0.000 description 9
- GMSNIKWWOQHZGF-UHFFFAOYSA-N 3-methyl-9H-xanthine Chemical compound O=C1NC(=O)N(C)C2=C1N=CN2 GMSNIKWWOQHZGF-UHFFFAOYSA-N 0.000 description 8
- 239000013078 crystal Substances 0.000 description 7
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 6
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 6
- 125000005188 oxoalkyl group Chemical group 0.000 description 6
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical class O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 239000012043 crude product Substances 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- OXTJFLMERRCYFJ-UHFFFAOYSA-N 3-methyl-7-(5-oxohexyl)purine-2,6-dione Chemical compound CN1C(=O)NC(=O)C2=C1N=CN2CCCCC(=O)C OXTJFLMERRCYFJ-UHFFFAOYSA-N 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- 206010042674 Swelling Diseases 0.000 description 3
- 230000008961 swelling Effects 0.000 description 3
- 229940065721 systemic for obstructive airway disease xanthines Drugs 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- FVXNLWRKEVZHKO-UHFFFAOYSA-N 1-chlorohexan-2-one Chemical compound CCCCC(=O)CCl FVXNLWRKEVZHKO-UHFFFAOYSA-N 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 239000003513 alkali Substances 0.000 description 2
- FQPFAHBPWDRTLU-UHFFFAOYSA-N aminophylline Chemical compound NCCN.O=C1N(C)C(=O)N(C)C2=C1NC=N2.O=C1N(C)C(=O)N(C)C2=C1NC=N2 FQPFAHBPWDRTLU-UHFFFAOYSA-N 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 231100000053 low toxicity Toxicity 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 125000004433 nitrogen atom Chemical group N* 0.000 description 2
- 125000004043 oxo group Chemical group O=* 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- YAPQBXQYLJRXSA-UHFFFAOYSA-N theobromine Chemical class CN1C(=O)NC(=O)C2=C1N=CN2C YAPQBXQYLJRXSA-UHFFFAOYSA-N 0.000 description 2
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 2
- 230000000304 vasodilatating effect Effects 0.000 description 2
- JKBKFWRCQSOAAN-UHFFFAOYSA-N 3-butyl-7-(5-oxohexyl)purine-2,6-dione Chemical compound O=C1NC(=O)N(CCCC)C2=C1N(CCCCC(C)=O)C=N2 JKBKFWRCQSOAAN-UHFFFAOYSA-N 0.000 description 1
- RDIDOICNEQWODO-UHFFFAOYSA-N 3-butyl-7h-purine-2,6-dione Chemical compound O=C1NC(=O)N(CCCC)C2=C1NC=N2 RDIDOICNEQWODO-UHFFFAOYSA-N 0.000 description 1
- TVZXSTTUKANBFF-UHFFFAOYSA-N 8-butyl-3,7-dihydropurine-2,6-dione Chemical compound N1C(=O)NC(=O)C2=C1N=C(CCCC)N2 TVZXSTTUKANBFF-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920001479 Hydroxyethyl methyl cellulose Polymers 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 102000014171 Milk Proteins Human genes 0.000 description 1
- 108010011756 Milk Proteins Proteins 0.000 description 1
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical class CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 230000003727 cerebral blood flow Effects 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000002360 explosive Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229940083747 low-ceiling diuretics xanthine derivative Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 235000021239 milk protein Nutrition 0.000 description 1
- 125000000896 monocarboxylic acid group Chemical group 0.000 description 1
- 239000012452 mother liquor Substances 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000020477 pH reduction Effects 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229960000278 theophylline Drugs 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940075420 xanthine Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
- C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19742457666 DE2457666A1 (de) | 1974-12-06 | 1974-12-06 | Arzneimittel, verfahren zur herstellung von dafuer geeigneten wirkstoffen und diese oxoalkyl-dialkyl-xanthine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CH620927A5 true CH620927A5 (en) | 1980-12-31 |
Family
ID=5932662
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CH1561475A CH620927A5 (en) | 1974-12-06 | 1975-12-02 | Process for the preparation of 3-alkyl-7-oxoalkylxanthines |
| CH18480A CH622520A5 (en) | 1974-12-06 | 1980-01-10 | Process for the preparation of novel 3-alkyl-7-oxoalkylxanthines |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CH18480A CH622520A5 (en) | 1974-12-06 | 1980-01-10 | Process for the preparation of novel 3-alkyl-7-oxoalkylxanthines |
Country Status (15)
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH608236A5 (enrdf_load_stackoverflow) * | 1974-01-22 | 1978-12-29 | Wuelfing J A Fa | |
| CA2030112A1 (en) * | 1989-11-24 | 1991-05-25 | Yasuo Ito | Xanthine compound, method for preparing thereof, and a pharmaceutical composition comprising the same |
| EP0570831A2 (de) * | 1992-05-20 | 1993-11-24 | Hoechst Aktiengesellschaft | Verwendung von Xanthinderivaten zur Behandlung von Nervenschädigungen nach Unterbrechung der Blutzirkulation |
-
1974
- 1974-12-06 DE DE19742457666 patent/DE2457666A1/de not_active Withdrawn
-
1975
- 1975-11-13 BE BE161822A patent/BE835521A/xx not_active IP Right Cessation
- 1975-11-13 NO NO753806A patent/NO143706C/no unknown
- 1975-11-20 ES ES442837A patent/ES442837A2/es not_active Expired
- 1975-11-20 ZA ZA757303A patent/ZA757303B/xx unknown
- 1975-11-28 AU AU87115/75A patent/AU496825B2/en not_active Expired
- 1975-12-01 FR FR7536754A patent/FR2293205A2/fr active Granted
- 1975-12-02 CH CH1561475A patent/CH620927A5/de not_active IP Right Cessation
- 1975-12-05 GB GB50049/75A patent/GB1533866A/en not_active Expired
- 1975-12-05 NL NL7514243A patent/NL7514243A/xx not_active Application Discontinuation
- 1975-12-05 FI FI753435A patent/FI753435A7/fi not_active Application Discontinuation
- 1975-12-05 SE SE7513759A patent/SE7513759L/xx unknown
- 1975-12-05 JP JP50144049A patent/JPS5182296A/ja active Pending
- 1975-12-05 DK DK550775A patent/DK550775A/da unknown
-
1977
- 1977-07-07 AT AT486877A patent/AT346362B/de not_active IP Right Cessation
-
1980
- 1980-01-10 CH CH18480A patent/CH622520A5/de not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| NO143706C (no) | 1981-04-01 |
| SE7513759L (sv) | 1976-06-08 |
| BE835521A (fr) | 1976-03-01 |
| DE2457666A1 (de) | 1976-06-10 |
| ATA486877A (de) | 1978-03-15 |
| NL7514243A (nl) | 1976-06-09 |
| AU8711575A (en) | 1977-06-02 |
| NO753806L (enrdf_load_stackoverflow) | 1976-06-09 |
| FI753435A7 (enrdf_load_stackoverflow) | 1976-06-07 |
| DK550775A (da) | 1976-06-07 |
| ES442837A2 (es) | 1977-05-16 |
| FR2293205B2 (enrdf_load_stackoverflow) | 1978-08-25 |
| AT346362B (de) | 1978-11-10 |
| FR2293205A2 (fr) | 1976-07-02 |
| JPS5182296A (en) | 1976-07-19 |
| CH622520A5 (en) | 1981-04-15 |
| NO143706B (no) | 1980-12-22 |
| GB1533866A (en) | 1978-11-29 |
| AU496825B2 (en) | 1978-11-02 |
| ZA757303B (en) | 1976-11-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE2330742C2 (de) | 1-(Oxoalkyl)-3-methyl-7-alkylxanthine, Verfahren zu ihrer Herstellung und diese enthaltende Arzneimittel | |
| AT363096B (de) | Verfahren zur herstellung von neuen phthalazinderivaten und deren salzen | |
| DE3028273C2 (enrdf_load_stackoverflow) | ||
| DE3028340C2 (de) | Amino-desoxy-1.4;3.6-dianhydro-hexit-nitrate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende pharmazeutische Zubereitungen | |
| EP0053767A1 (de) | Tricyclische Cytosinderivate zur Verwendung in Arzneimitteln und Verfahren zu ihrer Herstellung | |
| DE2714953C2 (de) | Arzneimittel | |
| DE1815808B2 (de) | 1 -(Alkanoylamiitophenoxy)-3-alkylamino-2-propanole deren Herstellungsverfahren und pharmazeutische Zusammensetzungen auf deren Basis | |
| CH620927A5 (en) | Process for the preparation of 3-alkyl-7-oxoalkylxanthines | |
| DE3028272C2 (enrdf_load_stackoverflow) | ||
| EP0018360A1 (de) | N-(5-Methoxybentofuran-2-ylcarbonyl)-N'-benzylpiperazin und Verfahren zu dessen Herstellung. | |
| DE1965711C3 (de) | l^-Dihydro-133-triazin-Derivate, Verfahren zu ihrer Herstellung und diese enthaltende Arzneimittel | |
| DE1545772B1 (de) | 7-(3'-Picolylamino-alkyl)-theophylline und deren nikotinsaure Salze | |
| AT344727B (de) | Verfahren zur herstellung von neuen 3-alkyl-7- (omega-1)-oxoalkylxanthinen | |
| DE2655130C3 (de) | Eine praktisch lösungsmittelfreie Kristallform des Cefacetril-Natriumsalzes | |
| DE924632C (de) | Verfahren zur Herstellung von Dialkylxanthinabkoemmlingen | |
| AT334392B (de) | Verfahren zur herstellung von neuen 1- oder 7-(omega-1)-oxoalkyl-3,7 (oder 1,3-)-dialkylxanthinen | |
| AT334391B (de) | Verfahren zur herstellung von neuen 1- oder 7-(omega-1)-oxoalkyl-3,7-(oder 1,3-)dialkylxanthinen | |
| DE2708827A1 (de) | Substituierte purinverbindungen, verfahren zu ihrer herstellung und pharmazeutische zubereitungen | |
| AT333301B (de) | Verfahren zur herstellung von neuen hydroxyalkylxanthinen | |
| AT359524B (de) | Verfahren zur herstellung von neuen mono-oder di-alkenylxanthinen | |
| AT333302B (de) | Verfahren zur herstellung von neuen hydroxyalkylxanthinen | |
| DE2366501C2 (de) | 1-Alkyl-3-methyl-7-oxoalkylxanthine, Verfahren zu ihrer Herstellung und diese enthaltende Arzneimittel | |
| AT333303B (de) | Verfahren zur herstellung von neuen hydroxyalkylxanthinen | |
| DE1915979C3 (de) | 1,3-Dimethyl-xanthin-Derivate und Verfahren zu ihrer Herstellung | |
| DE2408522A1 (de) | Aminderivate der azidophenole und verfahren zu ihrer herstellung |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PL | Patent ceased | ||
| PL | Patent ceased |